Loading...
Docoh

Affimed (AFMD)

News

From Benzinga Pro
Affimed Reports American Society Of Clinical Oncology Informed Co.'s Collaborator For AFM13-104 It Removed Oral Presentation From Upcoming Conference Program
6 May 22
Biotech, News, FDA, Events, General
Affimed N.V. (NASDAQ:AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the
Stocks That Hit 52-Week Lows On Friday
6 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 1043 companies hit new 52-week lows.
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
13 Apr 22
Biotech, M&A, News, Penny Stocks, Health Care, Small Cap, FDA, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal
Affimed Touts Encouraging Patient Responses For Its NK Cell Therapy In Lymphoma Settings
11 Apr 22
Biotech, News, Penny Stocks, Health Care, Small Cap, Movers, Trading Ideas, General
Affimed N.V. (NASDAQ: AFMD)
Affimed Presents Findings From The Dose-Escalation Phase Of The First-In-Human Study Of AFM24 In Patients With EGFR-Positive Solid Tumors At AACR Annual Meeting
8 Apr 22
News, FDA, Events
Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced data
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
31 Mar 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Recap: Affimed Q4 Earnings
31 Mar 22
Earnings, News
Affimed (NASDAQ:AFMD) reported its Q4 earnings results on Thursday, March 31, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
31 Mar 22
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For March 31, 2022
31 Mar 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.
Piper Sandler Initiates Coverage On Affimed with Overweight Rating, Announces Price Target of $7
31 Mar 22
News, Price Target, Initiation, Analyst Ratings
Piper Sandler analyst Do Kim initiates coverage on Affimed (NASDAQ:AFMD) with a Overweight rating and announces Price Target of $7.
Earnings Outlook For Affimed
30 Mar 22
Earnings
Affimed (NASDAQ:AFMD) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that Affimed will report an earnings per share (EPS) of $-0.17.
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
30 Mar 22
Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, FDA, Top Stories, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
27 Mar 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, Trading Ideas, General
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
20 Stocks Moving in Thursday's Pre-Market Session
24 Mar 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Mercurity Fintech Holding Inc. (NYSE: MFH) rose 91% to $4.03 in pre-market trading.
Cantor Fitzgerald Initiates Coverage On Affimed with Overweight Rating, Announces Price Target of $12
23 Feb 22
News, Price Target, Initiation, Analyst Ratings
Cantor Fitzgerald analyst Li Watsek initiates coverage on Affimed (NASDAQ:AFMD) with a Overweight rating and announces Price Target of $12.

Press releases

From Benzinga Pro
Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity
16 May 22
Health Care, Press Releases
Correlative science data from AFM24-101 clinical study support the rationale to develop AFM24 as monotherapy and in combination therapiesFirst preclinical data set on the combination of AFM28 with natural killer cells,
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
12 May 22
News, Press Releases
The novel bispecific innate cell engager AFM28 stimulates NK cells to destroy CD123-positive tumor cells via antibody-dependent cellular cytotoxicity.AFM28 induces effective lysis of hematological tumor cells even at
Affimed Provides Update on ASCO AFM13-104 Oral Presentation
6 May 22
Health Care, Press Releases
HEIDELBERG, Germany, May 06, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight
Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Association for Cancer Research (ASCO)
27 Apr 22
News, Health Care, Press Releases
A presentation on the phase 1/2 study evaluating cord blood-derived NK cells that are pre-complexed with the innate cell engager AFM13, in patients with CD30-positive lymphomas will be given in an oral abstract
Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares
18 Apr 22
News, IPOs, Press Releases
HEIDELBERG, Germany, April 18, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares
12 Apr 22
Markets, Press Releases
HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight
Affimed Announces Proposed Public Offering of Common Shares
12 Apr 22
Markets, Press Releases
HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight
Thinking about buying stock in Sailpoint Technologies, Veru, Eton Pharmaceuticals, AIM ImmunoTech, or Affimed?
11 Apr 22
Small Cap, Opinion, Press Releases
NEW YORK, April 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SAIL, VERU, ETON, AIM, and AFMD.
Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting
10 Apr 22
News, Health Care, Press Releases, General
100% objective response rate and improvement in the rate of complete responses (CR) from 38% to 62% after a second cycle in 13 patients treated at the recommended phase 2 dose (RP2D)Patients enrolled were
Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors
8 Apr 22
Health Care, Press Releases
The recommended phase 2 dose was determined at 480 mgAFM24 has demonstrated a well-managed safety profilePharmacodynamic activity was observed at doses of 160 mg and higherThe maximum tolerated dose was not reached and
Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress
31 Mar 22
Earnings, Press Releases
Completed enrollment for AFM13-202 monotherapy study, REDIRECT, and on track to report topline data in the second half of 2022Presented interim data in December 2021 of the combination study of AFM13 with NK cells
Affimed to Report Full Year 2021 Financial Results & Corporate Update on March 31, 2022
24 Mar 22
News, Press Releases
HEIDELBERG, Germany, March 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that
Affimed Announces Clinical Updates at the Annual Meeting of the American Association for Cancer Research
8 Mar 22
News, Health Care, Press Releases
In a Clinical Trials Plenary Session an update of the phase 1/2 study evaluating cord blood-derived NK cells that are pre-complexed with the innate cell engager AFM13 in patients with CD30-positive lymphomas will be
Fast-Growing German Biotech Affimed Chooses Generis CARA™ Life Science Platform for Clinical R&D Support
2 Mar 22
Generis, the creator of CARA™, the data and content management platform that helps life sciences companies transform their complex business processes, today announced that the ambitious German biotech company